Van Eck Associates Corp Ultragenyx Pharmaceutical Inc. Transaction History
Van Eck Associates Corp
- $80.1 Billion
- Q3 2024
A detailed history of Van Eck Associates Corp transactions in Ultragenyx Pharmaceutical Inc. stock. As of the latest transaction made, Van Eck Associates Corp holds 1,487 shares of RARE stock, worth $66,543. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,487
Previous 1,944
23.51%
Holding current value
$66,543
Previous $80,000
1.25%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding RARE
# of Institutions
325Shares Held
85.7MCall Options Held
520KPut Options Held
406K-
Vanguard Group Inc Valley Forge, PA9.95MShares$445 Million0.01% of portfolio
-
Black Rock Inc. New York, NY5.6MShares$251 Million0.01% of portfolio
-
Sands Capital Management, LLC Arlington, VA5.12MShares$229 Million0.91% of portfolio
-
Wellington Management Group LLP Boston, MA4.17MShares$186 Million0.04% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.07MShares$137 Million0.02% of portfolio
About Ultragenyx Pharmaceutical Inc.
- Ticker RARE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 70,036,896
- Market Cap $3.13B
- Description
- Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...